A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema

RECRUITING

NCT07216027

PHASE2

Sponsor: Pfizer

Summary

The purpose of this study is to learn if the study medicine (PF-08049820) is safe and effective for the treatment of atopic dermatitis (AD), also known as eczema, or atopic eczema. People with this condition may have severe itching and rashes on the skin. The study is seeking participants who: 1. Are 18 to 64 years of age; 2. Were confirmed to have AD at least 6 months ago; 3. Do not have a suitable prescribed medicine for AD; 4. Are considered by their doctors to have moderate to severe AD. The study has two stages (Stage 1 and Stage 2). In both stages, eligible participants will take either PF-08049820 or placebo as tablets by mouth daily for 12 weeks. A placebo does not have any medicine in it but looks just like the medicine being studied. Participants will visit the clinic on Day 1, Weeks 1, 2, 4, 6, 8 and 12. They will have a follow-up visit at Week 16. During this time, the participant's health and skin condition will be checked. They will have blood and urine tests. They will also have to answer questions about their health, skin condition, and how much their skin condition affects their lives. The experiences of participants receiving the study medicine will be compared to those receiving placebo. This will help to understand if PF-08049820 is safe and effective.

Official title: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08049820 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

Key Details

Gender

All

Age Range

18 Years - 64 Years

Study Type

INTERVENTIONAL

Enrollment

165

Start Date

2025-11-20

Completion Date

2028-02-02

Last Updated

2026-10-13

Healthy Volunteers

No

Conditions

Atopic Dermatitis Eczema, Atopic

Interventions

DRUG

PF-08049820

Tablet

DRUG

Placebo

Tablet

Locations (42)

Mayo Clinic Hospital

Phoenix, Arizona, United States

Mayo Clinic Specialty Building

Phoenix, Arizona, United States

Mayo Clinic

Scottsdale, Arizona, United States

Marvel Clinical Research

Huntington Beach, California, United States

Metropolis Dermatology - DTLA

Los Angeles, California, United States

Northridge Clinical Trials

Northridge, California, United States

Clinical Science Institute

Santa Monica, California, United States

Gsi Clinical Research

Margate, Florida, United States

Skin Research of South Florida

Miami, Florida, United States

Montefiore - Jacobi Dermatology Clinic